Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emoto, M.
Right arrow Articles by Oka, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emoto, M.
Right arrow Articles by Oka, Y.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:1166-1170, 2001
© 2001 by the American Diabetes Association, Inc.

Troglitazone Treatment Increases Plasma Vascular Endothelial Growth Factor in Diabetic Patients and Its mRNA in 3T3-L1 Adipocytes

Masahiro Emoto1, Takatoshi Anno1, Yutaka Sato1, Katsuya Tanabe1, Shigeru Okuya1, Yukio Tanizawa1, Akira Matsutani1, and Yoshitomo Oka1

1 Third Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan

Troglitazone is one of the thiazolidinediones, a new class of oral antidiabetic compounds that are ligands of peroxisome proliferator–activated receptor-{gamma}. This study on vascular endothelial growth factor (VEGF), also known as vascular permeability factor, was prompted by our clinical observation that the characteristics of troglitazone-induced edema were very similar to those caused by vascular hyperpermeability. When Japanese diabetic patients were screened for plasma VEGF, we found levels to be significantly (P < 0.001) increased in troglitazone-treated subjects (120.1 ± 135.0 pg/ml, n = 30) compared with those treated with diet alone (29.2 ± 36.1 pg/ml, n = 10), sulfonylurea (25.8 ± 22.2 pg/ml, n = 10), or insulin (24.6 ± 19.0 pg/ml, n = 10). Involvement of troglitazone in increased VEGF levels was further supported by the plasma VEGF levels in five patients before treatment (20.2 ± 7.0 pg/ml), after 3 months of troglitazone treatment (83.6 ± 65.9 pg/ml), and 3 months after discontinuation (28.0 ± 11.6 pg/ml). We further demonstrated that troglitazone, as well as rosiglitazone, at the plasma concentrations observed in patients, increased VEGF mRNA levels in 3T3-L1 adipocytes. VEGF is an angiogenic and mitogenic factor and is currently considered the most likely cause of neovascularization and hyperpermeability in diabetic proliferative retinopathy. Although increased VEGF may be beneficial for subjects with macroangiopathy and troglitazone is currently not available for clinical use, vascular complications, especially diabetic retinopathy, must be followed with great caution in subjects treated with thiazolidinediones.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. C. Granberry, J. B. Hawkins, and A. M. Franks
Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
Am. J. Health Syst. Pharm., May 1, 2007; 64(9): 931 - 936.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
Circulation, February 8, 2005; 111(5): 583 - 590.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C.-H. Wang, N. Ciliberti, S.-H. Li, P. E. Szmitko, R. D. Weisel, P. W.M. Fedak, M. Al-Omran, W.-J. Cherng, R.-K. Li, W. L. Stanford, et al.
Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial Lineage: A New Paradigm in Glitazone Pleiotropy
Circulation, March 23, 2004; 109(11): 1392 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo
Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone: EVIDENCE FOR INVOLVEMENT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) {gamma}-DEPENDENT AND PPAR{gamma}-INDEPENDENT SIGNALING PATHWAYS
J. Biol. Chem., January 23, 2004; 279(4): 2499 - 2506.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. Fukumura, A. Ushiyama, D. G. Duda, L. Xu, J. Tam, V. Krishna, K. Chatterjee, I. Garkavtsev, and R. K. Jain
Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis
Circ. Res., October 31, 2003; 93(9): e88 - 97.
[Abstract] [Full Text]

Home page
 CirculationHome page
S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus
Circulation, August 6, 2002; 106(6): 679 - 684.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.